Pride-HD is a Phase II clinical research study of an investigational drug called pridopidine in people who have a diagnosis of Huntington disease (HD). The purpose of this study to see what effect pridopidine has on movement, thinking, and behavior, compared to placebo (a capsule that looks like pridopidine but has no active ingredient), in people with Huntington’s Disease.

Pridopidine, the investigational drug being studied may have an effect on some of the symptoms of Huntington’s Disease that depend on dopamine. Dopamine is a substance that is naturally made by the human body. It is made in many areas of the brain, and affects how people behave, think and move. It has been suggested that changes in the way dopamine works in Huntington’s Disease creates signs and symptoms of the condition. This study is being conducted to determine if pridopidine helps with the signs and symptoms of Huntington’s Disease. 

Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington’s Disease Network (EHDN). 400 participants will be enrolled globally at approximately 51 study sites. Participants will receive either pridopidine or placebo for 26 weeks.

Click here for more detailed eligibility information and exclusion criteria.

For more information about enrolling in a site near you, contact: Teva US Medical Information 1-800-896-5855 or go to "Find a Clinical Trial Near You" on  There are 13 planned US sites that are currently recruiting patients or will be soon.